哥斯塔丁M可以逆转ABCG2介导的线粒激素抗性
Andrzej Błauż1, Marcin Wachulec1, Błażej Rychlik1
1Cytometry Laboratory, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Poland.
概括
这项研究开发了一种抗米托克桑的癌细胞模型,用于研究oncostatin M.
科学领域:
- 癌症生物学 癌症生物学
- 分子药理学分子药理学
背景情况:
- 多药耐药性 (MDR) 是癌症化疗中的一个主要挑战.
- 过度表达的ABC载体,如ABCG2和ABCB1,有助于MDR.
- 在调节MDR方面,哥斯塔丁M在调节MDR中的作用尚不清楚.
研究的目的:
- 开发和表征一种抗米托克桑抗性SW620细胞系,作为MDR研究的模型.
- 在这个模型系统中,研究哥斯塔丁M对MDR表型的影响.
主要方法:
- 通过选择方案开发一种抗米托克桑的SW620细胞系.
- 在RNA和蛋白质水平上对ABCG2和ABCB1表达具有抗性细胞的表征.
- 使用功能测试评估传送器功能.
- 用哥斯塔丁M治疗耐药细胞并评估MDR表型逆转.
主要成果:
- 选择的SW620变异在RNA和蛋白质水平上都表现出ABCG2和ABCB1的过度表达.
- 功能测试证实了这些排水的活性增加.
- 科斯塔丁M治疗部分逆转了MDR表型.
- 具体来说,哥斯塔丁M降低了ABCG2的过度表达,但没有降低ABCB1.
结论:
- 哥斯塔丁M证明了选择性下调ABCG2的能力,这是一个关键的MDR载体.
- 这种细胞因子显示出在癌症治疗中调节MDR的潜力.
- 开发出来的细胞系可以作为一个有价值的模型来研究细胞因子对MDR调节的研究.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:46Electron Transport Chain: Complex I and II
13.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K